Agency Information Collection Activities Comment Request, 63438-63439 [2024-17142]

Download as PDF 63438 Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices lotter on DSK11XQN23PROD with NOTICES1 comprehensive care to individuals with opioid use disorder (OUD), reduce harm, and effectively address the opioid crisis through service grants primarily to community-based organizations. This includes service grants that support the provision of MOUD such as methadone, buprenorphine and naltrexone which allow patients to receive treatment while maintaining their daily responsibilities and lives. Work in this branch will include engaging in community outreach and education efforts to raise awareness about the opioid epidemic, prevention strategies, and available treatment options. This is different from the work done in our state-based funding programs (State Opioid Response and Substance Use Prevention, Treatment, and Recovery Services Block Grants) which are housed in the Division of State and Community Systems (DSCS) and separate from the focus of the Division of Pharmacologic Therapies (DPT) which works with Opioid Treatment Programs to provide regulatory and provider support and does not fund opioid treatment. There is no overlap in the work of the existing divisions, DSCS and DPT, and the proposed OTB within the proposed DHSI. The OTB will manage the Medication-Assisted Treatment—Prescription Drug and Opioid Addiction (MAT–PDOA) and Targeted Capacity Expansion: Special Projects (TCE–SP) programs, both of which are authorized under section 509 of the PHSA, as amended. The purpose of MAT–PDOA is to provide resources to help expand and enhance access to MOUD. It is expected that this program will help to (1) increase access to MOUD for individuals with OUD, including individuals from diverse racial, ethnic, sexual and gender minority communities; and (2) decrease illicit opioid use and prescription opioid misuse. The purpose of TCE–SP is to implement targeted strategies for the provision of SUD or COD harm reduction, treatment, and/or recovery support services to support an underresourced population or unmet need identified by the community. Delegations of Authority All delegations and redelegations of authority to officers and employees of SAMHSA which were in effect immediately prior to the effective date of this reorganization shall continue to be in effect. Authority: 44 U.S.C. 3101. Xavier Becerra, Secretary of Health and Human Services. [FR Doc. 2024–17131 Filed 8–2–24; 8:45 am] BILLING CODE P VerDate Sep<11>2014 18:38 Aug 02, 2024 Jkt 262001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–0361. Proposed Project: Drug and Alcohol Warning Network (DAWN) (OMB No. 0930–0078)—Reinstatement With Change Under the Public Health Service Act (42 U.S.C. 290aa–4), SAMHSA is authorized to collect data on the number of individuals admitted to the emergency rooms of hospitals as a result of the abuse of alcohol or other drugs. DAWN is a nationwide public health surveillance system to improve hospital emergency department (ED) monitoring of substance use-related visits. It captures data on ED visits related to recent substance use and misuse directly from the electronic health records (EHR) of participating hospitals. The new DAWN helps SAMHSA and public health professionals, clinicians, and policymakers respond effectively to the opioid and substance misuse crisis in the United States. SAMHSA is requesting OMB approval of reinstatement with change of the DAWN data collections, to include following changes: • Revise the data collection title to ‘‘Drug and Alcohol Warning Network’’, replacing existing ‘abuse’ term and including ‘‘alcohol’’ in the title. • Remove drug-related death investigation records review component administered by state medical examiners (MEs) and individual medical examiners/coroners (ME/Cs). • Revise data collection procedures where participating hospitals can choose the direct chart review option (at the contractor’s operation center, homebased abstraction or on site at the hospital). Hospitals will also have the opportunity to select the machine learning with natural language processing (ML with NLP) option. The option for hospitals to use their own staff to abstract DAWN data as they did in the legacy DAWN is no longer offered. • Revise the hospital selection design of the ED component to a hybrid system PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 that combines sentinel hospitals and probability-based selection of hospitals from high priority suburban/rural areas and from the remaining areas in the United States. • Change the reporting and publication schedule to further increase the timeliness of the new DAWN data availability and delivery to SAMHSA. The new DAWN data are collected on an ongoing basis and could be available to SAMHSA on demand. The new DAWN data are delivered to SAMHSA and available for analysis at a more frequent intervals than the legacy DAWN. • Propose following changes to the ED Case Report Form: Æ Add ‘‘Center for Behavioral Health Statistics and Quality’’ to specify the center responsible for DAWN data collection. Æ Revise the data collection title to ‘‘Drug and Alcohol Warning Network’’ from ‘‘Drug Abuse Warning Network.’’ Æ Replace prior ‘‘Facility’’ data field title with ‘‘Hospital Emergency Department ID’’ to provide more precise description and ID number of the DAWN participating hospitals. Æ Q3 ‘‘Age’’: replace prior option of ‘‘less than 1 year’’ with two detailed options of ‘‘4 weeks (28 days) or younger’’ and ‘‘Between 4 weeks and one year old (>4 weeks, <1 year)’’ to enable new identification of neonatal substance issues. Æ Q4 ‘‘County of Residence’’: revise data field title from prior ‘‘patient’s home zip code’’ and add more accurate description on what data to be collected and clarify the purpose of data collection. Add new ‘‘Unable to determine county’’ option to improve data accuracy and account for geographical variation. Æ Q6 ‘‘Gender Identity’’ and Q7 ‘‘Sexual Orientation’’: added to provide inclusive measures and to align with SAMHSA’s efforts in enhancing behavioral health equities among diverse populations. Æ Q8 ‘‘Ethnicity’’ and Q9 ‘‘Race’’: revise prior data field ‘‘Race/Ethnicity’’ to align with OMB 1997 Standards for Maintaining, Collecting, And Presenting Federal Data on Race and Ethnicity (Statistical Policy Directive No. 15) and to improve data accuracy and comprehensiveness. Æ Q10 ‘‘Case Description’’: replace the word ‘‘drug(s)’’ with ‘‘substance(s)’’ to clarify that the DAWN collects data on all substances including alcohol. Add new instruction language of ‘‘Do not include information that could identify the patient or hospital’’ to provide clear instruction and specify the E:\FR\FM\05AUN1.SGM 05AUN1 63439 Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices importance of patient and hospital privacy protection. Æ Q11 ‘‘Substance(s) Involved and Route of Administration’’: add two new options of ‘‘transdermal’’ and ‘‘vaped’’ to improve the comprehensiveness of the list on how substance is administered by the patient. Remove ‘‘Mark if confirmed by toxicology test’’ and ‘‘alcohol involved?’’ Æ Q12 ‘‘Diagnosis’’: change the question order and move the data field after Q11. Revise prior instruction of ‘‘list up to 4 diagnoses’’ to ‘‘list all diagnoses’’ to enhances new DAWN’s ability to identify novel drug, drug trends, and drug outbreaks. Information collection activities Æ Q17 ‘‘Disposition’’: add new options and re-categorize disposition to improve data accuracy and comprehensiveness and better understand where the patient went after their ED visit. • Proposes a new Activity Report From to be submitted by the abstractors to collect information on the date of ED visits the abstractor has reviewed, counts of ED visits for that date, number of records reviewed, and number of left without being seen (LWBS) visits for the ED visit date if participating hospitals choose the direct chart review option. The estimated annual burden for the DAWN data collection is as follows: Æ Q13 ‘‘Type of Case’’: remove instruction language of ‘‘using the decision tree.’’ Revise the existing option of ‘‘seeking detox’’ to ‘‘seeking detox and/or substance abuse treatment only’’ and remove age restriction for ‘‘Alcohol only’’ option to include cases involving alcohol as the only substance of all ages. Æ Q14, Q15, and Q16 ‘‘Was naloxone/ buprenorphine/methadone administered to the patient in the ED’’: added to capture new data on the implementation of medication-assisted treatment for opioid use disorder in the emergency department setting and understand why buprenorphine and methadone is administered. Responses per respondent Number of respondents Hours per response (in hours) Total responses Total burden hours Average hourly wage Total annual cost Setting Up Activities * Initial outreach and recruitment (all hospitals) ......................................................... ED record provision setting up (direct chart review) ....................................................... ED record provision setting up (ML with NLP) ........................................................... 143 1 143 81.50 11,655 $48.72 $567,807 58 1 58 5.25 305 26.71 8,133 85 1 85 36.00 I 3,060 I 26.71 I 81,733 Ongoing Maintenance Activities Ongoing Maintenance (direct chart review) .. Ongoing Maintenance (ML with NLP) ........... 58 85 1 1 58 85 1.50 6.00 Totals ..................................................... ........................ ........................ ........................ ........................ * Setting up activities will be conducted once. Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Alicia Broadus, Public Health Advisor. [FR Doc. 2024–17142 Filed 8–2–24; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY Coast Guard lotter on DSK11XQN23PROD with NOTICES1 [Docket No. USCG–2024–0284] National Merchant Mariner Medical Advisory Committee; Vacancies U.S. Coast Guard, Department of Homeland Security. ACTION: Notice; request for applications. AGENCY: VerDate Sep<11>2014 18:38 Aug 02, 2024 Jkt 262001 The U.S. Coast Guard is accepting applications to fill twelve (12) vacancies on the National Merchant Mariner Medical Advisory Committee (Committee). This Committee advises, consults with, and makes recommendations to the Secretary of the Department of Homeland Security through the Commandant of the United States Coast Guard on matters relating to medical certification determinations for the issuance of licenses, certification of registry, and merchant mariners’ documents with respect to merchant mariners; medical standards and guidelines for the physical qualifications of operators of commercial vessels; medical examiner education; and medical research. DATES: Completed applications must reach the U.S. Coast Guard on or before September 4, 2024. ADDRESSES: Applications must include (a) a cover letter expressing interest in an appointment to the National Merchant Mariner Medical Advisory Committee, (b) a resume detailing the applicant’s relevant experience and qualifications for the position applied for (including the mariner reference SUMMARY: PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 87 510 I 15,616 26.71 26.71 I ........................ 2,324 13,622 I 673,619 number for professional mariners, and licensure, certification, or training information for health-care professionals), and (c) a brief biography. Applications should be submitted via email with subject line ‘‘Application for NMEDMAC’’ to pamela.j.moore@ uscg.mil. Ms. Pamela Moore, Alternate Designated Federal Officer of the National Merchant Mariner Medical Advisory Committee; telephone 202–372–1361 or email at pamela.j.moore@uscg.mil. FOR FURTHER INFORMATION CONTACT: The National Merchant Mariner Medical Advisory Committee is a Federal advisory committee. The Committee was established by section 601 of the Frank LoBiondo Coast Guard Authorization Act of 2018 (Pub. L. 115– 282, 132 Stat. 4192), and is codified in 46 U.S.C. 15104. The Committee operates under the provisions of the Federal Advisory Committee Act and 46 U.S.C. 15109. The Committee is required to meet at least once a year in accordance with 46 U.S.C. 15109(a). We expect the SUPPLEMENTARY INFORMATION: E:\FR\FM\05AUN1.SGM 05AUN1

Agencies

[Federal Register Volume 89, Number 150 (Monday, August 5, 2024)]
[Notices]
[Pages 63438-63439]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-17142]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities Comment Request

Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 276-0361.

Proposed Project: Drug and Alcohol Warning Network (DAWN) (OMB No.
0930-0078)--Reinstatement With Change

Under the Public Health Service Act (42 U.S.C. 290aa-4), SAMHSA is
authorized to collect data on the number of individuals admitted to the
emergency rooms of hospitals as a result of the abuse of alcohol or
other drugs. DAWN is a nationwide public health surveillance system to
improve hospital emergency department (ED) monitoring of substance use-
related visits. It captures data on ED visits related to recent
substance use and misuse directly from the electronic health records
(EHR) of participating hospitals. The new DAWN helps SAMHSA and public
health professionals, clinicians, and policymakers respond effectively
to the opioid and substance misuse crisis in the United States.
SAMHSA is requesting OMB approval of reinstatement with change of
the DAWN data collections, to include following changes:
Revise the data collection title to ``Drug and Alcohol
Warning Network'', replacing existing `abuse' term and including
``alcohol'' in the title.
Remove drug-related death investigation records review
component administered by state medical examiners (MEs) and individual
medical examiners/coroners (ME/Cs).
Revise data collection procedures where participating
hospitals can choose the direct chart review option (at the
contractor's operation center, home-based abstraction or on site at the
hospital). Hospitals will also have the opportunity to select the
machine learning with natural language processing (ML with NLP) option.
The option for hospitals to use their own staff to abstract DAWN data
as they did in the legacy DAWN is no longer offered.
Revise the hospital selection design of the ED component
to a hybrid system that combines sentinel hospitals and probability-
based selection of hospitals from high priority suburban/rural areas
and from the remaining areas in the United States.
Change the reporting and publication schedule to further
increase the timeliness of the new DAWN data availability and delivery
to SAMHSA. The new DAWN data are collected on an ongoing basis and
could be available to SAMHSA on demand. The new DAWN data are delivered
to SAMHSA and available for analysis at a more frequent intervals than
the legacy DAWN.
Propose following changes to the ED Case Report Form:
[cir] Add ``Center for Behavioral Health Statistics and Quality''
to specify the center responsible for DAWN data collection.
[cir] Revise the data collection title to ``Drug and Alcohol
Warning Network'' from ``Drug Abuse Warning Network.''
[cir] Replace prior ``Facility'' data field title with ``Hospital
Emergency Department ID'' to provide more precise description and ID
number of the DAWN participating hospitals.
[cir] Q3 ``Age'': replace prior option of ``less than 1 year'' with
two detailed options of ``4 weeks (28 days) or younger'' and ``Between
4 weeks and one year old (>4 weeks, <1 year)'' to enable new
identification of neonatal substance issues.
[cir] Q4 ``County of Residence'': revise data field title from
prior ``patient's home zip code'' and add more accurate description on
what data to be collected and clarify the purpose of data collection.
Add new ``Unable to determine county'' option to improve data accuracy
and account for geographical variation.
[cir] Q6 ``Gender Identity'' and Q7 ``Sexual Orientation'': added
to provide inclusive measures and to align with SAMHSA's efforts in
enhancing behavioral health equities among diverse populations.
[cir] Q8 ``Ethnicity'' and Q9 ``Race'': revise prior data field
``Race/Ethnicity'' to align with OMB 1997 Standards for Maintaining,
Collecting, And Presenting Federal Data on Race and Ethnicity
(Statistical Policy Directive No. 15) and to improve data accuracy and
comprehensiveness.
[cir] Q10 ``Case Description'': replace the word ``drug(s)'' with
``substance(s)'' to clarify that the DAWN collects data on all
substances including alcohol. Add new instruction language of ``Do not
include information that could identify the patient or hospital'' to
provide clear instruction and specify the

[[Page 63439]]

importance of patient and hospital privacy protection.
[cir] Q11 ``Substance(s) Involved and Route of Administration'':
add two new options of ``transdermal'' and ``vaped'' to improve the
comprehensiveness of the list on how substance is administered by the
patient. Remove ``Mark if confirmed by toxicology test'' and ``alcohol
involved?''
[cir] Q12 ``Diagnosis'': change the question order and move the
data field after Q11. Revise prior instruction of ``list up to 4
diagnoses'' to ``list all diagnoses'' to enhances new DAWN's ability to
identify novel drug, drug trends, and drug outbreaks.
[cir] Q13 ``Type of Case'': remove instruction language of ``using
the decision tree.'' Revise the existing option of ``seeking detox'' to
``seeking detox and/or substance abuse treatment only'' and remove age
restriction for ``Alcohol only'' option to include cases involving
alcohol as the only substance of all ages.
[cir] Q14, Q15, and Q16 ``Was naloxone/buprenorphine/methadone
administered to the patient in the ED'': added to capture new data on
the implementation of medication-assisted treatment for opioid use
disorder in the emergency department setting and understand why
buprenorphine and methadone is administered.
[cir] Q17 ``Disposition'': add new options and re-categorize
disposition to improve data accuracy and comprehensiveness and better
understand where the patient went after their ED visit.
Proposes a new Activity Report From to be submitted by the
abstractors to collect information on the date of ED visits the
abstractor has reviewed, counts of ED visits for that date, number of
records reviewed, and number of left without being seen (LWBS) visits
for the ED visit date if participating hospitals choose the direct
chart review option.
The estimated annual burden for the DAWN data collection is as
follows:

--------------------------------------------------------------------------------------------------------------------------------------------------------
Hours per
Information collection activities Number of Responses per Total response (in Total burden Average hourly Total annual
respondents respondent responses hours) hours wage cost
--------------------------------------------------------------------------------------------------------------------------------------------------------
Setting Up Activities *
--------------------------------------------------------------------------------------------------------------------------------------------------------
Initial outreach and recruitment (all 143 1 143 81.50 11,655 $48.72 $567,807
hospitals).............................
ED record provision setting up (direct 58 1 58 5.25 305 26.71 8,133
chart review)..........................
ED record provision setting up (ML with 85 1 85 36.00 3,060 26.71 81,733
NLP)...................................
--------------------------------------------------------------------------------------------------------------------------------------------------------
Ongoing Maintenance Activities
--------------------------------------------------------------------------------------------------------------------------------------------------------
Ongoing Maintenance (direct chart 58 1 58 1.50 87 26.71 2,324
review)................................
Ongoing Maintenance (ML with NLP)....... 85 1 85 6.00 510 26.71 13,622
---------------------------------------------------------------------------------------------------------------
Totals.............................. .............. .............. .............. .............. 15,616 .............. 673,619
--------------------------------------------------------------------------------------------------------------------------------------------------------
* Setting up activities will be conducted once.

Written comments and recommendations for the proposed information
collection should be sent within 30 days of publication of this notice
to www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under 30-day Review--Open for
Public Comments'' or by using the search function.

Alicia Broadus,
Public Health Advisor.
[FR Doc. 2024-17142 Filed 8-2-24; 8:45 am]
BILLING CODE 4162-20-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.